Recognition of genetic factors influencing the progression of hepatitis C: Potential for personalized therapy

Molecular Diagnosis and Therapy

Volumn 12, Issue 4, 2008, Pages 209-218

  Jonsson, Julie R ^a   Purdie, David M ^b   Clouston, Andrew D ^a   Powell, Elizabeth E ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GENENTECH INC   (United States)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Biomarkers; Genetic polymorphism; Hepatic fibrosis; Hepatitis C

Indexed keywords

ANGIOTENSIN; ANTIFIBROTIC AGENT; CHEMOKINE RECEPTOR CCR5; HFE PROTEIN; INTERLEUKIN 10; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGINTERFERON; RIBAVIRIN; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL THERAPY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; FATIGUE; FIBROGENESIS; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HUMAN; IMMUNE RESPONSE GENE; IMMUNOSUPPRESSIVE TREATMENT; LIPID METABOLISM; LIVER FIBROSIS; MENTAL DISEASE; MOLECULAR RECOGNITION; OXIDATIVE STRESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DEFECT; STEATOSIS; THYROID DISEASE; TREATMENT RESPONSE; VIRUS TYPING; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

HEPATITIS C VIRUS;

DISEASE PROGRESSION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; POLYMORPHISM, GENETIC;

EID: 53749084231     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256286     Document Type: Review

References (113)

1. WHO. Hepatitis C [online]. Available from URL: http://www.who.int/csr/ disease/hepatitis/whocdscsrlyo2003/en/index3.html#prevalence [Accessed 2008 Jul 4]
2. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31: 9-16
3. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002 Nov; 36 (5): S30-4
4. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003 Apr; 52 (4): 574-9
5. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral-hepatitis genome. Science 1989 Apr; 244 (4902): 359-62
6. Penin F, Dubuisson J, Rey FA, et al. Structural biology of hepatitis C virus. Hepatology 2004 Jan; 39 (1): 5-19
7. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005 Oct; 42 (4): 962-73
8. Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother 2006 Jan; 40 (1): 74-82
9. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002 Nov; 36 (5): S237-44
10. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003 May; 124 (6): 1711-9
11. Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am 2007 Dec; 36 (4): 1051-61
12. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 Sep; 358 (9286): 958-65
13. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 Sep; 347 (13): 975-82
14. Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003 Sep; 38 (3): 639-44
15. Herrine SK, Rossi S, Navarro VJ. Management of patients with chronic hepatitis C infection. Clin Exper Med 2006 Mar; 6 (1): 20-6
16. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006 Jan; 130 (1): 231-64
17. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004 Jun; 5 (4): 237-45
18. Friedman SL. Liver fibrosis: from bench to bedside. J Hepatol 2003; 38 Suppl. 1: S38-53
19. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007 Oct; 47 (4): 598-607
20. Kleiner DE. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 2005 Feb; 25 (1): 52-64
21. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997 Mar; 349 (9055): 825-32
22. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001 May; 34 (5): 730-9
23. Roudot-Thoraval F, Bastie A, Pawlotsky JM, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 1997 Aug; 26 (2): 485-90
24. Pontisso P, Gerotto M, Benvegnu L, et al. Coinfection by hepatitis B virus and hepatitis C virus. Antiviral Ther 1998; 3: 137-42
25. Tsai JF, Jeng JE, Ho MS, et al. Independent and additive effect modification of hepatitis C and B viruses infection on the development of chronic hepatitis. J Hepatol 1996 Mar; 24 (3): 271-6
26. Pol S, Fontaine H, Carnot F, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998 Jul; 29 (1): 12-9
27. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000 Apr; 32 (4): 673-84
28. Martin P, Dibisceglie AM, Kassianides C, et al. Rapidly progressive non-A, non-B-hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989 Dec; 97 (6): 1559-61
29. Soto B, SanchezQuijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997 Jan; 26 (1): 1-5
30. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999 Apr; 29 (4): 1215-9
31. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001 Jun; 33 (6): 1358-64
32. Hickman IJ, Powell EE, Prins JB, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003 Dec; 39 (6): 1042-8
33. Fartoux L, Poujol-Robert A, Guechot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005 Jul; 54 (7): 1003-8
34. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002 Nov; 36 (5): S35-46
35. Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44: S19-24
36. Teixeira R, Marcos LA, Friedman SL. Immunopathogenesis of hepatitis C infection and hepatic fibrosis: new insights into antifibrotic therapy in chronic hepatitis C. Hepatol Res 2007 Aug; 37 (8): 579-95
37. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005 Feb; 115 (2): 209-18
38. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008 May; 134 (6): 1655-69
39. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003 Mar; 37 (3): 493-503
40. Feld JJ, Liang TJ. Hepatitis C: identifying patients with progressive liver injury. Hepatology 2006 Feb; 43 (2): S194-206
41. Asselah T, Bieche I, Paradis V, et al. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007 Feb; 27 (1): 13-27
42. Osterreicher CH, Stickel F, Brenner AA. Genomics of liver fibrosis and cirrhosis. Semin Liver Dis 2007 Feb; 27 (1): 28-43
43. Yee LJ, Tang J, Herrera J, et al. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000 Aug; 1 (6): 386-90
44. Valenti L, Pulixi E, Fracanzani AL, et al. TNF alpha genotype affects TNF alpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J Hepatol 2005 Dec; 43 (6): 944-50
45. Bahr MJ, el Menuawy M, Boeker KHW, et al. Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int 2003 Dec; 23 (6): 420-5
46. Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 2003 Oct; 71 (2): 212-8
47. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000 Apr; 31 (4): 828-33
48. Rosen HR, McHutchison JG, Conrad AJ, et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002 Mar; 97 (3): 714-20
49. Yu ML, Dai CY, Chiu CC, et al. Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. Antiviral Res 2003 Jun; 59 (1): 35-40
50. Paladino N, Fainboim H, Theiler G, et al. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol 2006 Sep; 80 (18): 9144-50
51. Abbas Z, Moatter T, Hussainy A, et al. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol 2005; 11: 6656-61
52. Knapp S, Hennig BJW, Frodsham AJ, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003 Sep; 55 (6): 362-9
53. Abbott WGH, Rigopoulou E, Haigh P, et al. Single nucleotide polymorphisms in the interferon-gamma and interleukin-10 genes do not influence chronic hepatitis C severity or T-cell reactivity to hepatitis C virus. Liver Int 2004 Apr; 24 (2): 90-7
54. Hellier S, Frodsham AJ, Hennig BJW, et al. Association of genetic variants of the chemokine receptor MRS and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003 Dec; 38 (6): 1468-76
55. Richardson MM, Powell EE, Barrie HD, et al. A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. J Med Genet 2005 Jul; 42 (7): 6
56. Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003 Feb; 124 (2): 352-60
57. Wasmuth HE, Werth A, Mueller T, et al. CC chemokine receptor 5 Delta 32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. J Mol Med 2004 Jan; 82 (1): 64-9
58. Mascheretti S, Hinrichsen H, Ross S, et al. Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin Exper Immunol 2004 May; 136 (2): 328-33
59. Ruiz-Ferrer M, Barroso N, Antinolo G, et al. Analysis of CCR5-Delta 32 and CCR2-V64I polymorphisms in a cohort of Spanish HCV patients using real-time polymerase chain reaction and fluorescence resonance energy transfer technologies. J Viral Hepat 2004 Jul; 11 (4): 319-23
60. Goyal A, Suneetha PV, Kumar GT, et al. CCRS Delta 32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C. World J Gastroenterol 2006 Aug; 12 (29): 4721-6
61. Goulding C, Murphy A, MacDonald G, et al. The CCR5-D32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005 Aug; 54 (8): 1157-61
62. Tag CG, Mengsteab S, Hellerbrand C, et al. Analysis of the transforming growth factor-beta 1 (TGF-beta 1) codon 25 gene polymorphism by LightCycler-analysis in patients with chronic hepatitis C infection. Cytokine 2003 Dec; 24 (5): 173-81
63. Muhlbauer M, Bosserhoff AK, Hartmann A, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003 Oct; 125 (4): 1085-93
64. Glas J, Torok HP, Tonenchi L, et al. The-2518 promotor polymorphism in the MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection. Gastroenterology 2004 Jun; 126 (7): 1930-1
65. Bonkovsky HL, Salek J. No role of the-2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C. Gastroenterology 2005 Oct; 129 (4): 1361-2
66. Petit JM, Masson D, Minello A, et al. Lack of association between microsomal triglyceride transfer protein gene polymorphism and liver steatosis in HCV-infected patients. Mol Genet Metab 2006 Jun; 88 (2): 196-8
67. Martinelli ALC, Franco RF, Villanova MG, et al. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol 1999; 102 (3): 152-6
68. Smith BC, Grove J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998 Jun; 27 (6): 1695-9
69. Erhardt A, Maschner-Olberg A, Mellenthin C, et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003 Mar; 38 (3): 335-42
70. Gehrke SG, Stremmel W, Mathes I, et al. Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. J Mol Med 2003 Dec; 81 (12): 780-7
71. Hezode C, Cazeneuve C, Coue O, et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999 Dec; 31 (6): 979-84
72. Thorburn D, Curry G, Spooner R, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002; 50 (2): 248-52
73. Lebray P, Zylberberg H, Hue S, et al. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J Viral Hepat 2004 Mar; 11 (2): 175-82
74. Forrest EH, Thorburn D, Spence E, et al. Polymorphisms of the renin-angiotensin system and the severity of fibrosis in chronic hepatitis C virus infection. J Viral Hepat 2005 Sep; 12 (5): 519-24
75. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998 Dec; 17 (25): 3261-70
76. Verrecchia F, Mauviel A. TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell Signal 2004 Aug; 16 (8): 873-80
77. Moore KW, Malefyt RD, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol 2001; 19: 683-765
78. Wang SC, Ohata M, Schrum L, et al. Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem 1998 Jan; 273 (1): 302-8
79. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997 Feb; 24 (1): 1-8
80. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996 Aug; 86 (3): 367-77
81. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382 (6593): 722-5
82. Bedossa P, Paradis V. Transforming growth factor-beta (TBF-beta): a key role in liver fibrogenesis. J Hepatol 1995; 22: 37-42
83. Awad MR, El Gamel A, Hasleton P, et al. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-pi production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998 Oct; 66 (8): 1014-20
84. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997; 15: 675-705
85. Marra F, Romanelli RG, Giannini C, et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 1999 Jan; 29 (1): 140-8
86. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999 Jun; 259 (2): 344-8
87. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genet 1996 Aug; 13 (4): 399-408
88. Powell LW, Subramaniam VN, Yapp TR. Haemochromatosis in the new millennium. J Hepatol 2000; 32: 48-62
89. Bomford A. Genetics of haemochromatosis. Lancet 2002 Nov; 360 (9346): 1673-81
90. Pietrangelo A. Iron-induced oxidant stress in alcoholic liver fibrogenesis. Alcohol 2003 Jun; 30 (2): 121-9
91. Tung BY, Emond MJ, Bronner MP, et al. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003 Feb; 124 (2): 318-26
92. Noble NA, Border WA. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol 1997 Sep; 17 (5): 455-66
93. Inoue I, Nakajima T, Williams CS, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997 Apr; 99 (7): 1786-97
94. Ioannidis JPA. Genetic associations: false or true? Trends Mol Med 2003 Apr; 9 (4): 135-8
95. Todd JA. Statistical false positive or true disease pathway? Nature Genet 2006 Jul; 38 (7): 731-3
96. Huang HJ, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007 Aug; 46 (2): 297-306
97. Jorgenson E, Witte JS. A gene-centric approach to genome-wide association studies. Nature Rev Genet 2006 Nov; 7 (11): 885-91
98. Frayling TM. Commentary: genetic association studies see light at the end of the tunnel. Int J Epidemiol 2008 Feb; 37 (1): 133-5
99. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 2008 Feb; 37 (1): 120-32
100. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997 Feb; 112 (2): 463-72
101. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008 Jan; 48 (1): 28-34
102. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006 Apr; 55 (4): 529-35
103. Jonsson JR, Clouston AD, Ando Y, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001 Jul; 121 (1): 148-55
104. Paizis G, Gilbert RE, Cooper ME, et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 2001 Sep; 35 (3): 376-85
105. Terui Y, Saito T, Watanabe H, et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002 Oct; 36 (4): 1022
106. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004 Nov; 40 (5): 1222-5
107. Friedman SL, Bansal MB. Reversal of hepatic fibrosis: fact or fantasy? Hepatology 2006 Feb; 43 (2): S82-8
108. Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 2003 Mar; 348 (12): 1170-5
109. Lazarus R, Vercelli D, Palmer LJ, et al. Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunol Rev 2002 Dec; 190 (1): 9-25
110. Amos CI. Successful design and conduct of genome-wide association studies. Hum Mol Genet 2007 Oct; 16: R220-5
111. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005 Jul; 42 (1): 5-13
112. Paradis V, Mathurin P, Laurent A, et al. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol 1996 Dec; 49 (12): 998-1004
113. El-Serag HB, White DL, Mitra N. Genetic association studies: from "searching under the lamppost" to "fishing in the pond". Gastroenterology 2008; 134 (3): 662-4